swollen glands; swollen tonsils; stiff neck; migraine; neck pain; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from a regulatory authority. regulatory number: gb-mhra-webcovid-202202171836339000-kfgck. other case identifier(s): gb-mhra-adr 26614879. a 22 year-old patient received bnt162b2 (comirnaty), administration date 18dec2021 (lot number: fk9712) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: bnt162b2 (dose 1, single, batch/lot no: not reported), for covid-19 immunisation; bnt162b2 (dose 2, single, batch/lot no: not reported), for covid-19 immunisation. the following information was reported: neck pain (medically significant) with onset 20dec2021, outcome "not recovered", described as "neck pain"; lymphadenopathy (medically significant) with onset 03jan2022, outcome "not recovered", described as "swollen glands"; tonsillar hypertrophy (medically significant) with onset 03jan2022, outcome "not recovered", described as "swollen tonsils"; musculoskeletal stiffness (medically significant) with onset 03jan2022, outcome "not recovered", described as "stiff neck"; migraine (medically significant) with onset 03jan2022, outcome "not recovered", described as "migraine". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: negative, notes: no - negative covid-19 test. no follow-up attempts are possible. no further information is expected